Similar articles for PMID: 14623357

Year	Number of Results
1980	1
1982	1
1997	1
1998	1
1999	1
2000	2
2001	3
2002	3
2003	6
2004	6
2005	9
2006	8
2007	10
2008	13
2009	10
2010	6
2011	5
2012	12
2013	7
2014	6
2015	8
2016	5
2017	5
2018	8
2019	10
2020	12
2021	13
2022	13
2023	3
2024	0

1

The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.

van der Stelt M, Di Marzo V. van der Stelt M, et al. Eur J Pharmacol. 2003 Nov 7;480(1-3):133-50. doi: 10.1016/j.ejphar.2003.08.101. Eur J Pharmacol. 2003. PMID: 14623357 Review.

2

Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies.

El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET. El Khoury MA, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):36-50. doi: 10.1016/j.pnpbp.2011.12.005. Epub 2012 Jan 20. Prog Neuropsychopharmacol Biol Psychiatry. 2012. PMID: 22300746 Review.

3

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. Cabranes A, et al. Neurobiol Dis. 2005 Nov;20(2):207-17. doi: 10.1016/j.nbd.2005.03.002. Neurobiol Dis. 2005. PMID: 16242629

4

Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.

Mátyás F, Urbán GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I. Mátyás F, et al. Neuropharmacology. 2008 Jan;54(1):95-107. doi: 10.1016/j.neuropharm.2007.05.028. Epub 2007 Jun 22. Neuropharmacology. 2008. PMID: 17655884 Free PMC article.

5

[Role of endogenous cannabinoids in cerebral reward mechanisms].

Wenger T, Fürst S. Wenger T, et al. Neuropsychopharmacol Hung. 2004 Mar;6(1):26-9. Neuropsychopharmacol Hung. 2004. PMID: 15125311 Review. Hungarian.

6

The endocannabinoid system in Parkinson's disease.

Di Filippo M, Picconi B, Tozzi A, Ghiglieri V, Rossi A, Calabresi P. Di Filippo M, et al. Curr Pharm Des. 2008;14(23):2337-47. doi: 10.2174/138161208785740072. Curr Pharm Des. 2008. PMID: 18781984 Review.

7

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.

Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Dowie MJ, et al. Neuroscience. 2009 Sep 29;163(1):456-65. doi: 10.1016/j.neuroscience.2009.06.014. Epub 2009 Jun 10. Neuroscience. 2009. PMID: 19524019

8

The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice.

Kortleven C, Fasano C, Thibault D, Lacaille JC, Trudeau LE. Kortleven C, et al. Eur J Neurosci. 2011 May;33(10):1751-60. doi: 10.1111/j.1460-9568.2011.07648.x. Epub 2011 Mar 17. Eur J Neurosci. 2011. PMID: 21410793

9

The endocannabinoid system in brain reward processes.

Solinas M, Goldberg SR, Piomelli D. Solinas M, et al. Br J Pharmacol. 2008 May;154(2):369-83. doi: 10.1038/bjp.2008.130. Epub 2008 Apr 14. Br J Pharmacol. 2008. PMID: 18414385 Free PMC article. Review.

10

Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.

Lupica CR, Riegel AC. Lupica CR, et al. Neuropharmacology. 2005 Jun;48(8):1105-16. doi: 10.1016/j.neuropharm.2005.03.016. Neuropharmacology. 2005. PMID: 15878779 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

171 results

Results by year